What is Biogenes Technologies?
Biogenes Technologies is at the forefront of innovation in the life sciences, specializing in the design, development, and commercialization of animal-free aptamers. Their groundbreaking technology offers a sustainable and ethical alternative for simplifying diagnostics within the life science industry. The company's strategic focus is on serving clients who are actively seeking advanced, research-driven solutions, underscoring a commitment to ethical practices and scientific advancement.
How much funding has Biogenes Technologies raised?
Biogenes Technologies has raised a total of $5.7M across 1 funding round:
Series A
$5.7M
Series A (2023): $5.7M with participation from Pembangunan Ekuiti Sdn Bhd
Key Investors in Biogenes Technologies
Pembangunan Ekuiti Sdn Bhd
Pembangunan Ekuiti Sdn Bhd is an entity that participated in the Series A funding round. Further details on their investment focus are not publicly available.
What's next for Biogenes Technologies?
The recent major enterprise-level funding, including a significant strategic investment, indicates Biogenes Technologies is poised for an aggressive scaling phase. This capital will likely fuel expanded research and development initiatives, enhance commercialization efforts for their aptamer technology, and potentially broaden their market reach. The company's trajectory suggests a move towards solidifying its position as a key player in the diagnostics and life sciences market, with a focus on sustainable and animal-free solutions.
See full Biogenes Technologies company page
